Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
COVID-19 Novavax
About COVID-19 Novavax
Novavax developed a protein subunit vaccine using recombinant spike protein and a proprietary adjuvant. The vaccine showed approximately 90 percent efficacy in clinical trials. Novavax struggled with manufacturing and regulatory delays. The company received 1.6 billion dollars from the US governments Operation Warp Speed but did not receive FDA emergency use authorization until July 2022, well after Pfizer and Moderna had dominated the market. Novavax technology was more traditional than mRNA, which some vaccine hesitant individuals found appealing. The vaccine was authorized in Europe, the UK, India, and other countries before the US. Novavax shares lost most of their value between early 2021 and 2023. The case illustrates how manufacturing challenges can undermine promising vaccine technology.
Related Entries
COVID-19 Pfizer
The Pfizer BioNTech COVID-19 vaccine was the first mRNA vaccine authorized for emergency use, grante...
COVID-19 Moderna
The Moderna COVID-19 vaccine was developed in collaboration with the National Institute of Allergy a...
COVID-19 Johnson
The Johnson and Johnson COVID-19 vaccine used a modified adenovirus vector,different from the mRNA v...
COVID-19 AstraZeneca
The Oxford AstraZeneca COVID-19 vaccine was developed by scientists at the University of Oxford Jenn...